HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC - Trial NCT06364007
Access comprehensive clinical trial information for NCT06364007 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sulai Liu and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sulai Liu
Hunan Provincial People's Hospital
Timeline & Enrollment
Phase 2
Mar 03, 2024
Mar 31, 2026
Primary Outcome
ORR
Summary
The treatment options for unresectable HCC have rapidly developed, and immunotherapy has
 shown significant survival benefits in hepatocellular carcinoma. The STRIDE regimen of Single
 Tremelimumab (high, priming 300-mg dose) Regular Interval Durvalumab (1500 mg every 4 weeks)
 improved OS vs sorafenib in pts with unresectable HCC. In Asian region, HAIC is applied for
 HCC patients who are not suitable for surgical resection or local ablation treatment.
 Retrospective studies suggested a potent antitumor effect and survival benefit of HAIC plus
 programmed death-1 inhibitor and Lenvatinib. This phase II study was aimed to evaluate the
 efficacy and safety of STRIDE plus lenvatinib, given concurrently with HAIC in pts with
 unresectable HCC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364007
Non-Device Trial